As per DelveInsight, the Congenital Ichthyosis Market is anticipated to evolve immensely in the coming years owing to the increase in the initiatives toward control of drug resistance, the emergence of multi-drug resistance pathogens, and also the expected launch of emerging therapies in the market. Some of the key players such as Krystal Biotech, and others are actively working in the therapeutic market.
DelveInsight’s “Congenital Ichthyosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Ichthyosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Congenital Ichthyosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congenital Ichthyosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Congenital Ichthyosis: An Overview
Ichthyosis is a group of keratinization disorders that is clinically and etiologically heterogeneous and characterized by dryness, flaking, and peeling of the skin. Due to abnormalities in the structure of the stratum corneum, the increased transepidermal water loss causes excessive dryness. There are congenital and acquired forms of the disease.
Congenital form of ichthyosis can be defined as a group of monogenetic disorders of cornification, sometimes associated with systemic symptoms. There may be an abnormal quality or quantity of scale produced, the abnormal thickness of stratum corneum, or abnormal keratinocyte kinetics, often associated with skin inflammation.
The classification is based on the clinical presentation and distinguishes basically between nonsyndromic (including common ichthyosis, autosomal recessive congenital ichthyosis, keratinopathic ichthyosis, and other forms) and syndromic ichthyoses. The congenital forms include lamellar ichthyosis (LI), non-bullous congenital ichthyosiform erythroderma, and Harlequin ichthyosis. Harlequin ichthyosis, lamellar ichthyosis (LI), and congenital ichthyosiform erythroderma (CIE) fall under autosomal recessive congenital ichthyosis.
Congenital Ichthyosis Market Key Facts
As per the British Association of Dermatologists, Lamellar Ichthyosis is a rare form occurring in 1 in 200,000 live births in the United Kingdom.
According to the National Organization for Rare Disorders, Harlequin Ichthyosis affects males and females in equal numbers. This condition affects approximately one in 500,000 persons or
about seven births annually in the United States.
In the genetic mutation-specific cases of Lamellar Ichthyosis for 7MM, most of the cases are found with TGM1 mutation. It is estimated that about 1,817 cases of TGM1 mutation were estimated for the year 2017, during the study period (2017–2030).
As per Kelsell et al., (2011), Harlequin ichthyosis is rare, and both sexes are affected in equal numbers. It affects approximately one in 300,000 newborns.
Japan accounts for 16% of the 7MM patient population of Lamellar Ichthyosis in 2017.
Congenital Ichthyosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congenital Ichthyosis pipeline therapies. It also thoroughly assesses the Congenital Ichthyosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Congenital Ichthyosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Congenital Ichthyosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Congenital Ichthyosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Congenital Ichthyosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Congenital Ichthyosis Epidemiology, Segmented as –
Total Prevalent Cases of Congenital Ichthyosis in the 7MM [2019–2032]
Genetic Mutation-specific Cases of Congenital Ichthyosis in the 7MM [2019–2032]
Type-Specific Prevalent Cases of Congenital Ichthyosis in the 7MM [2019–2032]
Total Diagnosed Cases of Congenital Ichthyosis in the 7MM [2019–2032]
Total Treated Cases of Congenital Ichthyosis in the 7MM [2019–2032]
Congenital Ichthyosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congenital Ichthyosis market or expected to be launched during the study period. The analysis covers the Congenital Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Congenital Ichthyosis drugs based on their sale and market share.
The report also covers the Congenital Ichthyosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Congenital Ichthyosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Congenital Ichthyosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/congenital-ichthyosis-market
Congenital Ichthyosis Therapeutics Analysis
The unmet needs in the Congenital Ichthyosis Therapeutics market mainly exist due to the lack of novel and efficient therapies, as well as to improve the quality of life for patients with moderate to severe forms of Ichthyosis. To overcome the current challenges in the Congenital Ichthyosis Therapeutics market, several major pharma and biotech companies are developing therapies for Congenital Ichthyosis. Currently, Timber Pharmaceuticals is leading the therapeutics market with its Congenital Ichthyosis drug candidates in the mid to advanced stage of clinical development.
Congenital Ichthyosis Companies Actively Working in the Therapeutics Market Include
Timber Pharmaceuticals
Krystal Biotech Inc.
And Many Others
Emerging and Marketed Congenital Ichthyosis Therapies Covered in the Report Include:
TMB001: Timber Pharmaceuticals
TMB-001 (topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of CI. In a Phase 2a study, treatment with TMB-001 was shown to be well tolerated with minimal evidence of systemic absorption of isotretinoin. The Company is currently enrolling for phase 2b studies of TMB001.
KB105: Krystal Biotech
KB105, a replication-defective, non-integrating viral vector, utilizes the STAR-D (Skin TARgeted Delivery) platform to deliver functional human TGM-1 genes directly to the patient’s skin cells. The modified HSV-1 viral vector can penetrate a broad range of skin cells with its high payload capacity and low immunogenicity.
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Congenital Ichthyosis Competitive Intelligence Analysis
4. Congenital Ichthyosis Market Overview at a Glance
5. Congenital Ichthyosis Disease Background and Overview
6. Congenital Ichthyosis Patient Journey
7. Congenital Ichthyosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Congenital Ichthyosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Congenital Ichthyosis Unmet Needs
10. Key Endpoints of Congenital Ichthyosis Treatment
11. Congenital Ichthyosis Marketed Therapies
12. Congenital Ichthyosis Emerging Drugs and Latest Therapeutic Advances
13. Congenital Ichthyosis Seven Major Market Analysis
14. Attribute Analysis
15. Congenital Ichthyosis Market Outlook (In US, EU5, and Japan)
16. Congenital Ichthyosis Companies Active in the Market
17. Congenital Ichthyosis Access and Reimbursement Overview
18. KOL Views on the Congenital Ichthyosis Market
19. Congenital Ichthyosis Market Drivers
20. Congenital Ichthyosis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Trastuzumab Biosimilars Insight
“Trastuzumab Biosimilar Insight, 2023” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in the Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailAddress:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
